---
title: "Galaxy Medicare Ltd (GML) — Share Price, Financials & Analysis"
symbol: "GML"
company: "Galaxy Medicare Ltd"
canonical: "https://tapetide.com/stocks/GML"
isin: "INE09A801015"
nse_symbol: "GML"
sector: "Healthcare"
industry: "Medical Equipment"
market_cap_cr: 25.11
generated_at: "2026-09-13T19:35:52.813Z"
---

# Galaxy Medicare Ltd (GML)

Canonical page: https://tapetide.com/stocks/GML

## Company

- **NSE Symbol:** GML
- **ISIN:** INE09A801015
- **Sector:** Healthcare
- **Industry:** Medical Equipment
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2025-09-17
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** galaxy.in

## About

Incorporated in July 1992, Galaxy Medicare Limited manufactures and exports medical devices, POP bandages, and surgical dressings in India.[1]

## Latest Price

- **Price:** ₹16.9
- **Change:** +0.7 (+4.32%)
- **Open:** ₹17
- **Day High:** ₹17
- **Day Low:** ₹16.9
- **Previous Close:** ₹16.2
- **Volume:** 12000
- **As Of:** 2026-09-11T09:57:43+00:00

## Key Fundamentals

Observed at 2026-09-11T04:51:04.225202Z.

- **Market Cap:** ₹25.11 Cr
- **Classification:** SME
- **P/E (reported):** 7.4
- **Book Value:** ₹22.77
- **Price to Book:** 0.73
- **Dividend Yield:** 4.32%
- **ROE:** 13.95%
- **ROCE:** 21.05%
- **Debt to Equity:** 0.1
- **Revenue (yearly):** ₹40 Cr
- **Net Income:** ₹3.6 Cr
- **EBITDA:** ₹4.22 Cr
- **52-Week High:** ₹54
- **52-Week Low:** ₹15.15
- **RSI (14):** 38.82

## Tapetide Score

- **Score:** 59 / 100
- **Score date:** 2026-09-04
- **Archetype:** Average Quality, Undemanding Price
- **What it means:** The financials sit mid-range rather than strong, and the multiple is not demanding. Nothing here stands out in either direction, so the read comes down to which single pillar you weight most and whether the next results move it off the middle.
- **Pillar profile:** Quality: Average · Valuation: Cheap · Momentum: Flat
- **Percentile:** 84.7 (of 4473 scored stocks)
- **Confidence:** 86%
- **Data coverage:** 71%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 61.45 | 9% |
| growth | 41.17 | 9% |
| momentum | 57.48 | 12% |
| ownership | 53.1 | 24% |
| quality | 50.21 | 22% |
| valuation | 81.79 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Stock is trading at 0.64 times its book value

### Weaknesses

- The company has delivered a poor sales growth of 6.96% over past five years.
- Company has a low return on equity of 13.5% over last 3 years.

## Growth Rates

| Metric | 1Y | 3Y | 5Y |
| --- | --- | --- | --- |
| cash flow growth | 65.68% | 23.01% | -19.24% |
| ebitda margin growth | -28.08% | -33.81% | -5.11% |
| net income growth | 5.88% | 58% | 35% |
| revenue growth | -0.74% | 9% | 7% |
| roce | -11.89% | 50.04% | 14.84% |
| roe | -19.55% | 13.37% | 204.59% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
| --- | --- | --- | --- | --- |
| Sales | 17.24 | 21.96 | 18.73 | 21.27 |
| Expenses | 14.74 | 19.81 | 15.87 | 19.9 |
| Operating Profit | 2.5 | 2.15 | 2.86 | 1.37 |
| OPM % | 14.5 | 9.79 | 15.27 | 6.44 |
| Other Income | 0.55 | 0.52 | 0.33 | 0.98 |
| Interest | 0.38 | 0.31 | 0.11 | 0.16 |
| Depreciation | 0.25 | 0.25 | 0.3 | 0.25 |
| Profit before tax | 2.42 | 2.11 | 2.78 | 1.94 |
| Tax % | 29.34 | 21.8 | 27.34 | 27.32 |
| Net Profit | 1.71 | 1.66 | 2.02 | 1.4 |
| EPS in Rs | 1.44 | 1.4 | 1.33 | 0.92 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Sales | 28.57 | 30.94 | 35.84 | 38.86 | 40 |
| Expenses | 26.41 | 28.59 | 30.87 | 34.16 | 35.77 |
| Operating Profit | 2.16 | 2.35 | 4.97 | 4.7 | 4.23 |
| OPM % | 7.56 | 7.6 | 13.87 | 12.09 | 10.58 |
| Other Income | 0.5 | 1.72 | 1.18 | 1.07 | 1.31 |
| Interest | 0.8 | 0.95 | 0.94 | 0.74 | 0.28 |
| Depreciation | 0.82 | 1.12 | 0.48 | 0.5 | 0.55 |
| Profit before tax | 1.04 | 2 | 4.73 | 4.53 | 4.71 |
| Tax % | 30.77 | 21.5 | 21.56 | 25.61 | 27.39 |
| Net Profit | 0.72 | 1.57 | 3.71 | 3.37 | 3.42 |
| EPS in Rs | 2.57 | 5.16 | 3.13 | 2.84 | 2.25 |
| Dividend Payout % | 9.72 | 0 | 0 | 0 | 33.27 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Equity Capital | 2.8 | 3.04 | 11.86 | 11.86 | 15.17 |
| Reserves | 12.88 | 14.78 | 9.51 | 12.29 | 25.17 |
| Borrowings | 8.78 | 9.15 | 8.12 | 4.61 | 4.2 |
| Other Liabilities | 5.44 | 5.34 | 3.05 | 2.73 | 4.23 |
| Total Liabilities | 29.9 | 32.31 | 32.54 | 31.49 | 48.77 |
| Fixed Assets | 13.95 | 14.57 | 14.41 | 14.13 | 15.03 |
| CWIP | 0.2 | 0.06 | 0 | 0 | 0 |
| Investments | 2.98 | 2.69 | 3.11 | 2.82 | 2.87 |
| Other Assets | 12.77 | 14.99 | 15.02 | 14.54 | 30.87 |
| Total Assets | 29.9 | 32.31 | 32.54 | 31.49 | 48.77 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 5.56 | 3.65 | 2.71 | 4.49 | 1.77 |
| Cash from Investing Activity | -4.46 | -1.91 | -0.65 | 0.32 | -13.9 |
| Cash from Financing Activity | -1.11 | -1.8 | -2.08 | -4.72 | 12.09 |
| Net Cash Flow | 0 | -0.07 | -0.03 | 0.09 | -0.05 |
| Free Cash Flow | 1.09 | 2.9 | 2.5 | 4.37 | 0.21 |
| CFO/OP | 273 | 170 | 76 | 118 | 68 |

### Ratios

| Item | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Debtor Days | 93.26 | 106.65 | 74.65 | 64.72 | 69.53 |
| Inventory Days | 73.9 | 101.37 | 123.74 | 84.75 | 81.73 |
| Days Payable | 101.66 | 91.77 | 32.29 | 22.05 | 36.21 |
| Cash Conversion Cycle | 65.5 | 116.24 | 166.1 | 127.42 | 115.05 |
| Working Capital Days | 0.51 | 36.1 | 56.93 | 68.94 | 94.99 |
| ROCE % | — | — | 18.53 | 17.72 | 13.62 |

## Shareholding Pattern

### Quarterly

| Category | Mar 2025 | Sep 2025 | Mar 2026 |
| --- | --- | --- | --- |
| Promoters | 99.57% | 72.43% | 72.98% |
| FIIs | 0% | 0% | 0% |
| DIIs | 0% | 0% | 0% |
| Government | 0% | 0% | 0% |
| Public | 0.43% | 24.74% | 24.37% |
| Others | 0% | 2.83% | 2.65% |
| No. of Shareholders | 17 | 17 | 867 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 1 / 6 / 12

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 17.2 | Sell |
| EMA (10) | 17.22 | Sell |
| SMA (20) | 17.79 | Sell |
| EMA (20) | 17.49 | Sell |
| SMA (50) | 17.96 | Sell |
| EMA (50) | 17.88 | Sell |
| SMA (100) | 18.19 | Sell |
| EMA (100) | 18.5 | Sell |
| SMA (200) | 19.12 | Sell |
| EMA (200) | 20.07 | Sell |

### Oscillators — summary: **Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 42.84 | Neutral |
| MACD (12,26,9) | -0.3 | Sell |
| Stochastic (14,3,3) | 18.17 | Buy |
| ADX (14) | 12.65 | Neutral |
| Williams %R (14) | -73.02 | Neutral |
| ATR (14) | 0.57 | High Volatility |
| ROC (12) | -8.65 | Sell |
| Stoch RSI (14) | 27.07 | Neutral |
| UO (7,14,28) | 47 | Neutral |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 9 Jul - Submitted Regulation 74(5) certificate for quarter ended 30 June 2026. | [Certificate under SEBI (Depositories and Participants) Regulations, 2018 9 Jul - Submitted Regulation 74(5) certificate for quarter ended 30 June 2026.](https://nsearchives.nseindia.com/corporate/GALAXYMEDIPO_09072026140839_CERTIFICATE_UNDER__DEPOSITORIES_AND_PARTICIPANTS__REGULATION_2018.pdf) |
| 7 April 2026 - Submitted Regulation 74(5) certificate for quarter ended 31 March 2026. | [Certificate under SEBI (Depositories and Participants) Regulations, 2018 7 April 2026 - Submitted Regulation 74(5) certificate for quarter ended 31 March 2026.](https://nsearchives.nseindia.com/corporate/GALAXYMEDIPO_07042026163653_CERTIFICATE_UNDER__DEPOSITORIES_AND_PARTICIPANTS__REGULATION_2018.pdf) |
| 4 Sep - 34th AGM on 28 Sep 2026; final dividend Rs0.35/share; multiple director reappointments proposed. | [Shareholders meeting 4 Sep - 34th AGM on 28 Sep 2026; final dividend Rs0.35/share; multiple director reappointments proposed.](https://nsearchives.nseindia.com/corporate/GALAXYMEDIPO_04092026174828_NOTICE_OF_ANNUAL_GENERAL_MEETING.pdf) |
| 31 Aug - Board approved FY26 annual report, AGM on 28 Sep 2026, and appointed internal auditor and IR agency. | [Outcome of Board Meeting 31 Aug - Board approved FY26 annual report, AGM on 28 Sep 2026, and appointed internal auditor and IR agency.](https://nsearchives.nseindia.com/corporate/GALAXYMEDIPO_31082026184221_OUTCOME_OF_BOARD_MEETING___DATED___31_08_2026.pdf) |
| 31 Aug - Board approved FY26 annual report, AGM notice for 28 Sept 2026, and appointed auditors and advisors. | [Appointment 31 Aug - Board approved FY26 annual report, AGM notice for 28 Sept 2026, and appointed auditors and advisors.](https://nsearchives.nseindia.com/corporate/GALAXYMEDIPO_31082026185216_OUTCOME_OF_BOARD_MEETING___DATED___31_08_2026.pdf) |
| 29 May 2026 - Board approved FY26 audited results, 0.35 final dividend, and director/auditor reappointments. | [Appointment 29 May 2026 - Board approved FY26 audited results, 0.35 final dividend, and director/auditor reappointments.](https://nsearchives.nseindia.com/corporate/GALAXYMEDIPO_29052026203803_OUTCOME_OF_BOARD_MEETING___29_05_2026__NSE.pdf) |
| 29 May 2026 - Board approved FY26 audited results, 0.35 dividend, and several director and secretarial auditor reappointments. | [Appointment 29 May 2026 - Board approved FY26 audited results, 0.35 dividend, and several director and secretarial auditor reappointments.](https://nsearchives.nseindia.com/corporate/GALAXYMEDIPO_29052026202912_OUTCOME_OF_BOARD_MEETING___29_05_2026__NSE.pdf) |
| 29 May 2026 - Board approved FY2025-26 audited results, Rs0.35 dividend, and several director reappointments on 29 May 2026. | [Appointment 29 May 2026 - Board approved FY2025-26 audited results, Rs0.35 dividend, and several director reappointments on 29 May 2026.](https://nsearchives.nseindia.com/corporate/GALAXYMEDIPO_29052026203134_OUTCOME_OF_BOARD_MEETING___29_05_2026__NSE.pdf) |
| 29 May 2026 - Board approved audited FY2026 results, 0.35 final dividend, and multiple director and auditor reappointments. | [Appointment 29 May 2026 - Board approved audited FY2026 results, 0.35 final dividend, and multiple director and auditor reappointments.](https://nsearchives.nseindia.com/corporate/GALAXYMEDIPO_29052026202650_OUTCOME_OF_BOARD_MEETING___29_05_2026__NSE.pdf) |
| 29 May 2026 - 29 May 2026 board approved FY26 audited results, recommended 0.35 dividend, and reappointed directors/auditor. | [Appointment 29 May 2026 - 29 May 2026 board approved FY26 audited results, recommended 0.35 dividend, and reappointed directors/auditor.](https://nsearchives.nseindia.com/corporate/GALAXYMEDIPO_29052026202203_OUTCOME_OF_BOARD_MEETING___29_05_2026__NSE.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Annual Report 2026 from nse](https://archives.nseindia.com/annual_reports/SME_AR_31411_GML_2025_2026_A_100768115_04092026181811.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:35:52.813Z.